<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01498016</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-Busulfan</org_study_id>
    <nct_id>NCT01498016</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia</brief_title>
  <official_title>Pharmacokinetic Study of Intravenous Busulfan as Conditioning Regimen for Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous Busulfan (iv-Bu) is commonly used as part of preparation regimen for allogeneic
      hematopoietic stem cell transplantation for patients with acute leukemia. Though the
      pharmacokinetics data are available for population from America, Europe and Japan or Korea in
      Asia, there are no data in Chinese population. It is shown that high Bu concentration are
      associated with the toxicity such as veno-occlusion disease and lower concentration is
      correlated with reduced anti-leukemia effect, thus the monitoring of Bu and/or the strategy
      to achieve an optimal target Bu concentration are accepted to avoid toxicity while maintain
      the anti-leukemia effect which may overall improve the outcome of allo-SCT. Thus we conduct
      the pharmacokinetic study in Chinese population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients received intravenous Busulfan based conditioning regimen for allogeneic stem
      cell transplantation.

      Intravenous Busulfan (iv-Bu) was given 1.6mg/kg twice daily for 4 days as in the conditioning
      regimen.

      Blood samples were obtained after first and 7th dose of iv Bulsulfan.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>predose, 0,1,2,3,4,6,8,12,24,48,72, 96 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>Iv-Busulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iv busulfan 1.6mg/kg given q12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Iv busulfan 1.6mg/kg q12h D1- D4</description>
    <arm_group_label>Iv-Busulfan</arm_group_label>
    <other_name>study group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with acute myeloid or lymphoblastic leukemia in 1st or second remission

          -  age 18-55 years

          -  with inform consent

          -  no contraindication for allogeneic transplantation: active infection, allergy to
             FLu/Bu/CTX, liver and renal function damage

          -  HLA matched related (6/6) or unrelated donors (at least 8/10)

        Exclusion Criteria:

          -  age less than 18 years or over 56 years

          -  HLA mismatched related donor

          -  liver function/renal function damage (over 2 X upper normal range)

          -  with mental disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong HU, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong HU, M.D.</last_name>
    <phone>86-21-64370045-601818</phone>
    <email>hujiong@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplantation Center, RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU, M.D.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>601818</phone_ext>
      <email>hujiong@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood &amp;^ Marrow Transplantation Center</investigator_title>
  </responsible_party>
  <keyword>acute leukemia</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>busulfan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

